Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art. Issue 1 (13th November 2019)

• Record Type: Journal Article
• Authors: Albano, Domenico; Bruno, Alberto; Patti, Caterina; Micci, Giuseppe; Midiri, Massimo; Tarella, Corrado; Galia, Massimo
• Is Part Of: Hematological oncology. Volume 38:Issue 1(2020)
• Page Start: 12
• Page End: 21
• Publication Date: 2019-11-13
• Subjects: lymphoma -- magnetic resonance imaging -- positron emission tomography -- whole‐body imaging; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2676
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole‐body MRI (WB‐MRI) as a radiation‐free alternative to standard imaging procedures. WB‐MRI seems a less histology‐dependent functional imaging test than 18 F‐fluorodeoxyglucose‐positron emission tomography/CT ( 18 F‐FDG‐PET/CT). In patients with FDG‐avid lymphomas, such as diffuse large B‐cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18 F‐FDG‐PET/CT remains the imaging reference standard for staging, with WB‐MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB‐MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB‐MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas.